O	0	10	Hyperforin	Hyperforin	NN	B-NP
O	11	17	blocks	block	VBZ	B-VP
B-Cell	18	28	neutrophil	neutrophil	NN	B-NP
O	29	39	activation	activation	NN	I-NP
O	40	42	of	of	IN	B-PP
O	43	49	matrix	matrix	NN	B-NP
O	50	67	metalloproteinase	metalloproteinase	NN	I-NP
O	67	68	-	-	HYPH	B-NP
O	68	69	9	9	CD	I-NP
O	69	70	,	,	,	I-NP
O	71	79	motility	motility	NN	I-NP
O	80	83	and	and	CC	I-NP
O	84	95	recruitment	recruitment	NN	I-NP
O	95	96	,	,	,	O
O	97	100	and	and	CC	O
O	101	110	restrains	restrain	VBZ	B-VP
O	111	123	inflammation	inflammation	NN	B-NP
O	123	124	-	-	HYPH	O
O	124	133	triggered	trigger	VBN	B-VP
O	134	146	angiogenesis	angiogenesis	NN	B-NP
O	147	150	and	and	CC	I-NP
B-Organ	151	155	lung	lung	NN	I-NP
O	156	164	fibrosis	fibrosis	NN	I-NP
O	164	165	.	.	.	O

O	166	176	Hyperforin	Hyperforin	NN	B-NP
O	177	178	(	(	(	O
O	178	181	Hyp	Hyp	NN	B-NP
O	181	182	)	)	)	O
O	182	183	,	,	,	O
O	184	185	a	a	DT	B-NP
O	186	196	polyphenol	polyphenol	NN	I-NP
O	196	197	-	-	HYPH	I-NP
O	197	207	derivative	derivative	NN	I-NP
O	208	210	of	of	IN	B-PP
O	211	213	St	St	NNP	B-NP
O	213	214	.	.	.	O

O	215	219	John	John	NNP	B-NP
O	219	220	'	'	POS	B-NP
O	220	221	s	s	NN	I-NP
O	222	226	wort	wort	NN	I-NP
O	227	228	(	(	(	O
O	228	237	Hypericum	Hypericum	NNP	B-NP
O	238	248	perforatum	perforatum	NNP	I-NP
O	248	249	)	)	)	O
O	249	250	,	,	,	O
O	251	254	has	have	VBZ	B-VP
O	255	262	emerged	emerge	VBN	I-VP
O	263	265	as	as	IN	B-PP
O	266	269	key	key	JJ	B-NP
O	270	276	player	player	NN	I-NP
O	277	280	not	not	RB	B-CONJP
O	281	285	only	only	RB	I-CONJP
O	286	288	in	in	IN	B-PP
O	289	292	the	the	DT	B-NP
O	293	307	antidepressant	antidepressant	NN	I-NP
O	308	316	activity	activity	NN	I-NP
O	317	319	of	of	IN	B-PP
O	320	323	the	the	DT	B-NP
O	324	329	plant	plant	NN	I-NP
O	330	333	but	but	CC	B-CONJP
O	334	338	also	also	RB	I-CONJP
O	339	341	as	as	IN	B-PP
O	342	344	an	an	DT	B-NP
O	345	354	inhibitor	inhibitor	NN	I-NP
O	355	357	of	of	IN	B-PP
O	358	366	bacteria	bacteria	NNS	B-NP
B-Cell	367	377	lymphocyte	lymphocyte	NN	I-NP
O	378	381	and	and	CC	I-NP
B-Cell	382	387	tumor	tumor	NN	I-NP
I-Cell	388	392	cell	cell	NN	I-NP
O	393	406	proliferation	proliferation	NN	I-NP
O	406	407	,	,	,	O
O	408	411	and	and	CC	O
O	412	418	matrix	matrix	NN	B-NP
O	419	430	proteinases	proteinas	NNS	I-NP
O	430	431	.	.	.	O

O	432	434	We	We	PRP	B-NP
O	435	441	tested	test	VBD	B-VP
O	442	449	whether	whether	IN	B-SBAR
O	450	452	as	as	RB	B-CONJP
O	453	457	well	well	RB	I-CONJP
O	458	460	as	as	IN	I-CONJP
O	461	471	inhibiting	inhibit	VBG	B-VP
O	472	481	leukocyte	leukocyte	NN	B-NP
O	482	490	elastase	elastase	NN	I-NP
O	491	492	(	(	(	O
O	492	494	LE	LE	NN	B-NP
O	494	495	)	)	)	O
O	496	504	activity	activity	NN	B-NP
O	504	505	,	,	,	O
O	506	509	Hyp	Hyp	NN	B-NP
O	510	515	might	might	MD	B-VP
O	516	518	be	be	VB	I-VP
O	519	528	effective	effective	JJ	B-ADJP
O	529	531	in	in	IN	B-PP
O	532	542	containing	contain	VBG	B-VP
O	543	547	both	both	CC	O
B-Cell	548	565	polymorphonuclear	polymorphonuclear	JJ	B-NP
I-Cell	566	576	neutrophil	neutrophil	NN	I-NP
I-Cell	577	578	(	(	(	O
I-Cell	578	581	PMN	PMN	NN	B-NP
I-Cell	581	582	)	)	)	O
I-Cell	583	592	leukocyte	leukocyte	NN	B-NP
O	593	604	recruitment	recruitment	NN	I-NP
O	605	608	and	and	CC	O
O	609	620	unfavorable	unfavorable	JJ	B-NP
O	621	629	eventual	eventual	JJ	I-NP
B-Tissue	630	636	tissue	tissue	NN	I-NP
O	637	646	responses	response	NNS	I-NP
O	646	647	.	.	.	O

O	648	651	The	The	DT	B-NP
O	652	659	results	result	NNS	I-NP
O	660	664	show	show	VBP	B-VP
O	665	669	that	that	IN	B-SBAR
O	669	670	,	,	,	O
O	671	678	without	without	IN	B-PP
O	679	688	affecting	affect	VBG	B-VP
O	689	691	in	in	FW	B-NP
O	692	697	vitro	vitro	FW	I-NP
O	698	703	human	human	JJ	I-NP
B-Cell	704	707	PMN	PMN	NN	I-NP
O	708	717	viability	viability	NN	I-NP
O	718	721	and	and	CC	I-NP
O	722	731	chemokine	chemokine	NN	I-NP
O	731	732	-	-	HYPH	B-NP
O	732	740	receptor	receptor	NN	I-NP
O	741	751	expression	expression	NN	I-NP
O	751	752	,	,	,	O
O	753	756	Hyp	Hyp	NN	B-NP
O	757	758	(	(	(	O
O	758	760	as	as	IN	B-PP
O	761	767	stable	stable	JJ	B-NP
O	768	788	dicyclohexylammonium	dicyclohexylammonium	NN	I-NP
O	789	793	salt	salt	NN	I-NP
O	793	794	)	)	)	O
O	795	798	was	be	VBD	B-VP
O	799	803	able	able	JJ	B-ADJP
O	804	806	to	to	TO	B-VP
O	807	814	inhibit	inhibit	VB	I-VP
O	815	817	in	in	IN	B-PP
O	818	819	a	a	DT	B-NP
O	820	824	dose	dose	NN	I-NP
O	824	825	-	-	HYPH	B-NP
O	825	834	dependent	dependent	JJ	I-NP
O	835	841	manner	manner	NN	I-NP
O	842	847	their	their	PRP$	B-NP
O	848	858	chemotaxis	chemotaxis	NN	I-NP
O	859	862	and	and	CC	I-NP
O	863	876	chemoinvasion	chemoinvasion	NN	I-NP
O	877	878	(	(	(	O
O	878	882	IC50	IC50	NN	B-NP
O	882	883	=	=	SYM	B-VP
O	883	884	1	1	CD	B-NP
O	885	891	microM	microM	NN	I-NP
O	892	895	for	for	IN	B-PP
O	896	900	both	both	DT	B-NP
O	900	901	)	)	)	O
O	901	902	;	;	:	O
O	903	907	this	this	DT	B-NP
O	908	914	effect	effect	NN	I-NP
O	915	918	was	be	VBD	B-VP
O	919	929	associated	associate	VBN	I-VP
O	930	934	with	with	IN	B-PP
O	935	936	a	a	DT	B-NP
O	937	944	reduced	reduce	VBN	I-NP
O	945	955	expression	expression	NN	I-NP
O	956	958	of	of	IN	B-PP
O	959	962	the	the	DT	B-NP
O	963	971	adhesion	adhesion	NN	I-NP
O	972	980	molecule	molecule	NN	I-NP
O	981	986	CD11b	CD11b	NN	I-NP
O	987	989	by	by	IN	B-PP
O	990	996	formyl	formyl	NN	B-NP
O	996	997	-	-	HYPH	B-NP
O	997	1000	Met	Met	NN	I-NP
O	1000	1001	-	-	HYPH	B-NP
O	1001	1004	Leu	Leu	NN	I-NP
O	1004	1005	-	-	HYPH	B-NP
O	1005	1008	Phe	Phe	NN	I-NP
O	1008	1009	-	-	HYPH	B-NP
O	1009	1019	stimulated	stimulate	VBN	I-NP
B-Cell	1020	1031	neutrophils	neutrophil	NNS	I-NP
O	1032	1035	and	and	CC	I-NP
O	1036	1041	block	block	NN	I-NP
O	1042	1044	of	of	IN	B-PP
O	1045	1047	LE	LE	NN	B-NP
O	1047	1048	-	-	HYPH	O
O	1048	1057	triggered	trigger	VBN	B-VP
O	1058	1068	activation	activation	NN	B-NP
O	1069	1071	of	of	IN	B-PP
O	1072	1075	the	the	DT	B-NP
O	1076	1086	gelatinase	gelatinase	NN	I-NP
O	1087	1093	matrix	matrix	NN	I-NP
O	1094	1111	metalloproteinase	metalloproteinase	NN	I-NP
O	1111	1112	-	-	HYPH	B-NP
O	1112	1113	9	9	CD	I-NP
O	1113	1114	.	.	.	O

B-Cell	1115	1118	PMN	PMN	NN	B-NP
O	1118	1119	-	-	HYPH	B-PP
O	1119	1128	triggered	trigger	VBN	B-NP
O	1129	1141	angiogenesis	angiogenesis	NN	I-NP
O	1142	1144	is	be	VBZ	B-VP
O	1145	1149	also	also	RB	I-VP
O	1150	1157	blocked	block	VBN	I-VP
O	1158	1160	by	by	IN	B-PP
O	1161	1165	both	both	CC	B-NP
O	1166	1171	local	local	JJ	I-NP
O	1172	1181	injection	injection	NN	I-NP
O	1182	1185	and	and	CC	I-NP
O	1186	1191	daily	daily	JJ	I-NP
O	1192	1193	i	i	NN	I-NP
O	1193	1194	.	.	.	I-NP
O	1194	1195	p	p	NN	I-NP
O	1195	1196	.	.	.	I-NP
O	1197	1211	administration	administration	NN	I-NP
O	1212	1214	of	of	IN	B-PP
O	1215	1218	the	the	DT	B-NP
O	1219	1222	Hyp	Hyp	NN	I-NP
O	1223	1227	salt	salt	NN	I-NP
O	1228	1230	in	in	IN	B-PP
O	1231	1233	an	an	DT	B-NP
O	1234	1245	interleukin	interleukin	NN	I-NP
O	1245	1246	-	-	HYPH	B-NP
O	1246	1247	8	8	CD	I-NP
O	1247	1248	-	-	HYPH	I-NP
O	1248	1255	induced	induce	VBN	I-NP
O	1256	1262	murine	murine	JJ	I-NP
O	1263	1268	model	model	NN	I-NP
O	1268	1269	.	.	.	O

O	1270	1281	Furthermore	Furthermore	RB	B-ADVP
O	1281	1282	,	,	,	O
O	1283	1284	i	i	NN	B-NP
O	1284	1285	.	.	.	O
O	1285	1286	p	p	NN	B-NP
O	1286	1287	.	.	.	O
O	1288	1297	treatment	treatment	NN	B-NP
O	1298	1302	with	with	IN	B-PP
O	1303	1306	Hyp	Hyp	NN	B-NP
O	1307	1314	reduces	reduce	VBZ	B-VP
O	1315	1320	acute	acute	JJ	B-NP
B-Cell	1321	1324	PMN	PMN	NN	I-NP
O	1325	1336	recruitment	recruitment	NN	I-NP
O	1337	1340	and	and	CC	O
O	1341	1349	enhances	enhance	VBZ	B-VP
O	1350	1360	resolution	resolution	NN	B-NP
O	1361	1363	in	in	IN	B-PP
O	1364	1365	a	a	DT	B-NP
B-Organ	1366	1375	pulmonary	pulmonary	JJ	I-NP
O	1376	1385	bleomycin	bleomycin	NN	I-NP
O	1385	1386	-	-	HYPH	B-NP
O	1386	1393	induced	induce	VBN	I-NP
O	1394	1406	inflammation	inflammation	NN	I-NP
O	1407	1412	model	model	NN	I-NP
O	1412	1413	,	,	,	O
O	1414	1427	significantly	significantly	RB	B-VP
O	1428	1436	reducing	reduce	VBG	I-VP
O	1437	1447	consequent	consequent	JJ	B-NP
O	1448	1456	fibrosis	fibrosis	NN	I-NP
O	1456	1457	.	.	.	O

O	1458	1463	These	These	DT	B-NP
O	1464	1471	results	result	NNS	I-NP
O	1472	1480	indicate	indicate	VBP	B-VP
O	1481	1485	that	that	IN	B-SBAR
O	1486	1489	Hyp	Hyp	NN	B-NP
O	1490	1492	is	be	VBZ	B-VP
O	1493	1494	a	a	DT	B-NP
O	1495	1503	powerful	powerful	JJ	I-NP
O	1504	1508	anti	anti	AFX	I-NP
O	1508	1509	-	-	HYPH	I-NP
O	1509	1521	inflammatory	inflammatory	JJ	I-NP
O	1522	1530	compound	compound	NN	I-NP
O	1531	1535	with	with	IN	B-PP
O	1536	1547	therapeutic	therapeutic	JJ	B-NP
O	1548	1557	potential	potential	NN	I-NP
O	1557	1558	,	,	,	O
O	1559	1562	and	and	CC	O
O	1563	1567	they	they	PRP	B-NP
O	1568	1577	elucidate	elucidate	VBP	B-VP
O	1578	1589	mechanistic	mechanistic	JJ	B-NP
O	1590	1594	keys	key	NNS	I-NP
O	1594	1595	.	.	.	O

